Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life

References

• International Agency for Research on Cancer: Global Cancer Observatory [accessed 2021 Dec 1]. Available from: https://gco.iarc.fr/
   Google Scholar
• Orphanet: The portal for rare diseases and orphan drugs [accessed 2021 Dec 1]. Available from: https://www.orpha.net/consor/cgi-bin/index.php?lng=EN
   Google Scholar
• Pakkala S, Owonikoko TK. Immune checkpoint inhibitors in small cell lung cancer. J Thorac Dis. 2018;10(Suppl 3):S460–S467.
   PubMed Web of Science ®Google Scholar
• Anbazhagan R, Tihan T, Bornman DM, et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 1999;59(20):5119–5122.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang R, Garces YI, et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer. 2010;67(2):221–226.
   PubMed Web of Science ®Google Scholar
• TECENTRIQ Prescribing Information. Genentech, Inc. 2022.
   Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer [published correction appears in J Clin Oncol. 2019 Dec 1;37(34):3327]. J Clin Oncol. 2016;34(31):3740–3748.
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75–83.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, CASPIAN investigators, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Salgia R, Wang X, et al. Randomized phase II study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008;26(6):870–876.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39(12):1349–1359.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021;32(5):631–641.
   PubMed Web of Science ®Google Scholar
• Pujol JL, Greillier L, Audigier-Valette C, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. J Thorac Oncol. 2019;14(5):903–913.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Każarnowicz A, Karaseva N, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020;31(2):310–317.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Garassino MC, Chen Y, et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer. 2020;149:46–52.
   PubMed Web of Science ®Google Scholar
• Li LY, Wang H, Chen X, et al. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019;132(23):2790–2794.
   PubMed Web of Science ®Google Scholar
• Zhou K, Zhou J, Huang J, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 2019;130:1–4.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [published correction appears in Lancet Oncol. 2016 Jul;17 (7):e270] [published correction appears in lancet oncol. 2019 feb;20(2):e70]. Lancet Oncol. 2016;17(7):883–895.
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618–627.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQLC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life. Eur J Cancer. 1994;30(5):635–642.
   Web of Science ®Google Scholar
• Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and Meta-analysis. JAMA Oncol. 2020;6(3):375–384.
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS Meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–1698.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, Society for Immunotherapy of Cancer Toxicity Management Working Group, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104.
   PubMed Web of Science ®Google Scholar
• Vedadi A, Shakik S, Brown MC, et al. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. Qual Life Res. 2021;30(2):445–454.
   PubMed Web of Science ®Google Scholar
• Povsic M, Enstone A, Wyn R, et al. Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: a systematic literature review (SLR). PLoS One. 2019;14(7):e0219622.
   PubMed Web of Science ®Google Scholar
• Cramer-van der Welle CM, Schramel FMNH, Peters BJM, et al. Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer [published online ahead of print, 2020 Dec 9]. Pharmacoepidemiol Drug Saf. 2021;30(4):445–450.
   PubMed Web of Science ®Google Scholar
• Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021;156:41–49.
   PubMed Web of Science ®Google Scholar
• Schwartzberg L, Korytowsky B, Penrod JR, et al. Real-world clinical impact of immune checkpoint inhibitors in patients with advanced/metastatic Non-Small cell lung cancer after platinum chemotherapy. Clin Lung Cancer. 2019;20(4):287–296.e284.
   PubMed Web of Science ®Google Scholar
• Miao K, Zhang X, Wang H, et al. Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China. Front Oncol. 2022;12:859938.
   PubMed Web of Science ®Google Scholar